Antiagregación plaquetaria: stents, isquemia y sangrado ¿Qué sabemos al respecto? / Platelet antiaggregation: stents, ischemia and bleeding What do we know about it?
Rev. méd. Maule
;
37(1): 105-113, jun. 2022. tab, ilus
Article
Dans Espagnol
| LILACS
| ID: biblio-1397776
ABSTRACT
Antiplatelet therapy and percutaneous coronary intervention are two of the most important interventions in the management of coronary artery disease. In the last 20 years there has been groundbreaking advances in the pharmacotherapy and stent technology. Bleeding is the most feared complication of antiplatelet therapy, mainly due to the increase in major adverse cardiovascular events besides the bleeding itself. Different clinical decision tools have developed with the aim to define which patients have a high ischemic or bleeding risk, thus individualizing treatment.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Antiagrégants plaquettaires
/
Association de médicaments
/
Intervention coronarienne percutanée
Type d'étude:
Étude pronostique
Limites du sujet:
Humains
langue:
Espagnol
Texte intégral:
Rev. méd. Maule
Thème du journal:
Médicament
Année:
2022
Type:
Article
Pays d'affiliation:
Chili
Institution/Pays d'affiliation:
Hospital Regional de Talca/CL
/
Universidad Católica del Maule/CL
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS